-
-
-
-
-
-
-
ORIC Pharmaceuticals, Inc. (ORIC) Misses Q1 EPS by 2c
-
-
-
-
-
-
-
Jones Trading on ORIC Pharmaceuticals (ORIC): "We see pressure" following Ipsen's Tazverik withdrawal
-
-
-
-
-
-
-
Piper Sandler Starts ORIC Pharmaceuticals (ORIC) at Overweight
-
-
-
-
-
-
-
Wolfe Research Starts ORIC Pharmaceuticals (ORIC) at Peerperform
-
-
-
-
-
-
-
ORIC Pharmaceuticals, Inc. (ORIC) Misses Q2 EPS by 3c
-
-
-
-
-
-
-
JPMorgan on ORIC Pharamceuticals (ORIC): 'Top Pick', 'ORIC shares should be ~2-4X current levels', PT $20
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on ORIC Pharamceuticals (ORIC)
-
456,277 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

